Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘ARV–471’

The weird, the wild, and the wonderful

Seeing a Nawlins style paddle boat on a river in Germany is kind of weird, wild, and wonderful all at once!

Following the ESMO Breast Cancer conference in Berlin this weekend, we have some data we’d like to draw your attention to.

These are also key topics for discussion in the broader context of what’s happening in advanced breast cancer and where the field is (or perhaps ought to be) heading next.

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

ESMO22 Preview 1 – what to watch out for in breast cancer

Time to make your selections!

This year seems to be going all to quickly as we have arrived in time for the annual ESMO Preview series.

This year we have a lot of topics to cover from a review of various solid tumour types, novel targets and developmental therapeutics, hematologic malignancies, as well as various IO and cell therapy related readouts.

As always, the goal of our previews is to not only provide some context for what to expect, but also to highlight potential success and failures since not all of the trials have been headlined by the companies concerned.

It’s all to easy to forget agents in the same class of therapeutics can produce quite different outcomes despite similarly looking trial designs, as we will find out…

To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

A twist in chemical moeity

These bunches in nature often remind me of ball and spoke chemical structures

One of the hot topics at the recent AACR meeting was undoubtedly protein degradation, including the PROTACs from Arvinas, monoDACs from C4 Therapeutics and IRAKIMiD from Kymera, not to mention a bunch of other targets.

Certainly there’s plenty of science to review for a new mini-series with a lot to unpack from each.

In the first part of this new series we focus on Arvinas and what we can learn from the details provided, plus an in-depth expert interview.

To learn more about our ongoing post AACR21 meeting analysis and expert interviews to get a heads up on key oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Highlights and commentary on key AACR21 data presentations

It’s time for some commentary and insights regarding important emerging data from the AACR meeting.

The route to success in oncology R&D is always paved with gold, after all, although big ticket acquisitions may take some of the sting out of the tail.

As always, there were some hidden gems in the AACR21 program — in the first of our post meeting critiques, we take a careful look at the what’s behind the veneer.

We have a round baker’s dozen of early new product development compounds and explore them all to find out what interesting, as well as where there are potential pointers for future challenges which may need to be addressed…

To learn more about the AACR21 data and get a heads up on our oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

AACR21 Preview 1 Emerging targets for protein degradation and molecular glues

Saw this arrangement in a local orchid garden, which reminded me of the blobs used to illustrate E3 ligase – protein complexes

In the first of our new season AACR Preview series, we continue to explore what’s happening in the protein degradation and molecular glue niche.

Yes, it’s still early days and there’s much we don’t know but it should be useful to follow the developments and see what can be learned.

Perhaps a few observers might be surprised at the sheer range of targets being evaluated in R&D pipelines since some of these are definitely not of the every day kitchen sink kind of variety.  There is no doubt in my mind some will be easier or much harder than others, but what is intriguing is the depth of the details which are starting to emerge of late.

So what’s in store and which abstracts stood out this year in this niche?

To learn more about the AACR21 data and get a heads up on our oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Important learnings from targeted therapies from SABCS

In the last post from SABCS, we looked at what’s new on the translational front with the MYC oncogene in terms of breast cancer.

This time around we turn our attention to other targets and subsets of interest, which don’t involve immunotherapy – more on the latter in a separate article.

Today’s featured image is inspired by my dear friend Jody Schoger and Lisa Adams, who inspired us to find a little beauty in the world each day, no matter how hard it might seem.  2015 was very bad year for losing wonderful BioTwitter chums in the breast cancer community – they may be gone, but never forgotten 🙁

In particular, we highlight new developments in four key areas of interest, with some intriguing observations to discuss…

To learn more from our oncology analysis and get a heads up on the latest insights and commentary pertaining to the SABCS meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Will the next generation SERDs make an impact in ER+ HER2- breast cancer?

It’s time for another landscape review of a particular class of drugs in early development.

Here we take an in-depth look at the emerging SERD landscape in ER+ metastatic breast cancer. There’s a lot going on the ER+HER2- niche these days after a bit of a lull once we saw the CDK4/6 inhibitors approved so it’s a good opportunity for some extended colour commentary on what could become a hot area in oncology over the next couple of years.

Overcoming or delaying the onset of therapeutic resistance is going to be important, but how do we go about achieving this?

Historically we have seen some success in inhibiting the activity of the estrogen receptor (ER) as a driver of oncogenic activity, but what if we could degrade the aberrant protein instead? Would this approach yield some further benefits for people with advanced breast cancer?

There are quite a few companies, big and small, involved in this space so there’s still much to play for, especially in terms of figuring out what the ideal drug should look like and which combinations might be most useful. We also highlight key upcoming conference presentations to watch out for – hint: there’s quite a lot of them!

To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the ASCO and second AACR virtual meetings, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!